Search tips
Search criteria 


Logo of eidLink to Publisher's site
Emerg Infect Dis. 2000 May-Jun; 6(3): 228–237.
PMCID: PMC2640864

A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States.


To assess the benefits of intervention programs against Helicobacter pylori infection, we estimated the baseline curves of its incidence and prevalence. We developed a mathematical (compartmental) model of the intrinsic dynamics of H. pylori, which represents the natural history of infection and disease progression. Our model divided the population according to age, infection status, and clinical state. Case-patients were followed from birth to death. A proportion of the population acquired H. pylori infection and became ill with gastritis, duodenal ulcer, chronic atrophic gastritis, or gastric cancer. We simulated the change in transmissibility consistent with the incidence of gastric cancer and duodenal ulcer over time, as well as current H. pylori prevalence. In the United States, transmissibility of H. pylori has decreased to values so low that, should this trend continue, the organism will disappear from the population without targeted intervention; this process, however, will take more than a century.

Full Text

The Full Text of this article is available as a PDF (211K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Telford JL, Ghiara P. Prospects for the development of a vaccine against Helicobacter pylori. Drugs. 1996 Dec;52(6):799–804. [PubMed]
  • Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA. The cohort effect and Helicobacter pylori. J Infect Dis. 1993 Jul;168(1):219–221. [PubMed]
  • Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995;9 (Suppl 2):45–51. [PubMed]
  • Kuipers EJ. Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther. 1997 Apr;11 (Suppl 1):71–88. [PubMed]
  • Graham DY. Helicobacter pylori: its epidemiology and its role in duodenal ulcer disease. J Gastroenterol Hepatol. 1991 Mar-Apr;6(2):105–113. [PubMed]
  • Schultze V, Hackelsberger A, Günther T, Miehlke S, Roessner A, Malfertheiner P. Differing patterns of Helicobacter pylori gastritis in patients with duodenal, prepyloric, and gastric ulcer disease. Scand J Gastroenterol. 1998 Feb;33(2):137–142. [PubMed]
  • Sonnenberg A. Temporal trends and geographical variations of peptic ulcer disease. Aliment Pharmacol Ther. 1995;9 (Suppl 2):3–12. [PubMed]
  • Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer. 1985 Feb 15;35(2):173–177. [PubMed]
  • Sipponen P. Helicobacter pylori gastritis--epidemiology. J Gastroenterol. 1997 Apr;32(2):273–277. [PubMed]
  • Hansson LE, Nyrén O, Hsing AW, Bergström R, Josefsson S, Chow WH, Fraumeni JF, Jr, Adami HO. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med. 1996 Jul 25;335(4):242–249. [PubMed]
  • Blaser MJ, Chyou PH, Nomura A. Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res. 1995 Feb 1;55(3):562–565. [PubMed]
  • Correa P, Cuello C, Duque E, Burbano LC, Garcia FT, Bolanos O, Brown C, Haenszel W. Gastric cancer in Colombia. III. Natural history of precursor lesions. J Natl Cancer Inst. 1976 Nov;57(5):1027–1035. [PubMed]
  • Feldman RA, Eccersley AJ, Hardie JM. Epidemiology of Helicobacter pylori: acquisition, transmission, population prevalence and disease-to-infection ratio. Br Med Bull. 1998;54(1):39–53. [PubMed]
  • Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology. 1997 Dec;113(6):1983–1991. [PubMed]
  • Valle J, Kekki M, Sipponen P, Ihamäki T, Siurala M. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol. 1996 Jun;31(6):546–550. [PubMed]
  • Bonnevie O. The incidence of duodenal ulcer in Copenhagen county. Scand J Gastroenterol. 1975;10(4):385–393. [PubMed]
  • Bonnevie O. The incidence of gastric ulcer in Copenhagen county. Scand J Gastroenterol. 1975;10(3):231–239. [PubMed]
  • Karnes WE, Jr, Samloff IM, Siurala M, Kekki M, Sipponen P, Kim SW, Walsh JH. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology. 1991 Jul;101(1):167–174. [PubMed]
  • Sonnenberg A. Factors which influence the incidence and course of peptic ulcer. Scand J Gastroenterol Suppl. 1988;155:119–140. [PubMed]
  • Sonnenberg A. Geographic and temporal variations in the occurrence of peptic ulcer disease. Scand J Gastroenterol Suppl. 1985;110:11–24. [PubMed]
  • Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther. 1995;9 (Suppl 2):59–69. [PubMed]
  • Olshansky SJ, Carnes BA. Ever since Gompertz. Demography. 1997 Feb;34(1):1–15. [PubMed]
  • Kurata JH, Honda GD, Frankl H. The incidence of duodenal and gastric ulcers in a large health maintenance organization. Am J Public Health. 1985 Jun;75(6):625–629. [PubMed]
  • Williams JR, Nokes DJ, Medley GF, Anderson RM. The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect. 1996 Feb;116(1):71–89. [PMC free article] [PubMed]
  • Porco TC, Blower SM. Quantifying the intrinsic transmission dynamics of tuberculosis. Theor Popul Biol. 1998 Oct;54(2):117–132. [PubMed]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention